KBC Securities - BIOTALYS NV (BTLS) Morning Notes : BTLS BB

Report

KBC Securities

Thomas Vranken

Morning Notes : BTLS BB

: BTLS BB

17/09/2024 1 EN

Underlying

BIOTALYS NV

See profile

BE0974386188 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

Biotalys FIRST LOOK: BioFun-8 strengthens the pipeline

Biotalys announced the addition of a new biofungicide program to the pipeline. Biofun-8 leverages Biotalys' Agrobody platform and will target Alternaria, an important leaf spot fungus in fruits, vegetables and potato crops. Biotalys estimates a market opportunity around $ 1.1bn. We reiterate our € 6 TP and Buy rating.

10h / 1m 10h / 1m 1 EN

KBC Securities

Morning Notes : DSFIR NA, ONTEX BB, SEQUA BB, UCB BB, BTLS BB

: DSFIR NA, ONTEX BB, SEQUA BB, UCB BB, BTLS BB

10h / 24m 10h / 24m 1 EN

Sequana Medical € 6m convertible and debt restructuring extend runway into 1Q25

Sequana reported 1H24 results and announced a new convertible loan of € 3.05m (additional tranche of € 3.05m), extending its runway into 1Q25. The company is exploring separating the DSR and alfapump businesses into Hive-Downs to solve for the lack of synergy between programs. Additionally, Sequana restructured its debt with Kreos, PMV, Belfius, and Sensinnovat. Responses to the FDA 90 Day letter will submitted on 1 October, and alfapump PMA approval continues to be expected by 1Q25.

9h / 51m 9h / 51m 1 EN

Thomas Vranken

Thomas Vranken

Biotalys FIRST LOOK: BioFun-8 strengthens the pipeline

10h / 1m 10h / 1m 1 EN

Thomas Vranken

Thomas Vranken

UCB Highlighting the unmet needs in HS

In a capital markets call yesterday, UCB provided more insight into the HS data with two KOLs. The presenters emphasized the importance of Bimzelx' clinical remission rates and reduction in draining tunnels. We raise our peak sales estimate for HS to € 1.1bn, and increase our TP from € 168 to € 173.

10h / 6m 10h / 6m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : BTLS BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Biotalys FIRST LOOK: BioFun-8 strengthens the pipeline

Morning Notes : DSFIR NA, ONTEX BB, SEQUA BB, UCB BB, BTLS BB

Sequana Medical € 6m convertible and debt restructuring extend runway into 1Q25

Biotalys FIRST LOOK: BioFun-8 strengthens the pipeline

UCB Highlighting the unmet needs in HS

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe